A Focus On Long-term Growth In Biotech - Dr. Jason Kantor - Rbc Capital Markets

Healthcare >> Analyst Interviews >> November 15, 2010

Dr. Jason Kantor is a Managing Director of Credit Suisse Group and a Senior Analyst covering the U.S. biotechnology sector, with a focus on small and midcap stocks. He joined Credit Suisse Group in 2012. Prior to joining the bank, Dr. Kantor held positions of Managing Director and Senior Biotechnology Analyst at RBC Capital Markets, 2005 to 2012; Managing Director and Senior Biotechnology Analyst at WR Hambrecht + Co, 2002 to 2005; and Vice President in equity research at J.P. Morgan Chase & Co from 1998 to 2002. Dr. Kantor’s health care expertise covers several important categories including oncology, cardiology, antibody technology and infectious disease. He has had several independent recognitions including: Fortune All-Star Analyst in 2004, The Wall Street Journal ranked him number two in 2004 and number four in 2010 in its Best on the Street survey, and the Financial Times and StarMine ranked him number two for earnings estimations in 2010. Dr. Kantor received his B.A. cum laude in biology from the University of California, San Diego, and his Ph.D. in cell and developmental biology from Harvard University. Profile

TWST: What is happening in the biotech sector now? Are things getting better?

Mr. Kantor: Biotechnology is a maturing industry, and I don't mean that in the classic sense of there is no more growth

Join for free to read a longer excerpt or purchase this article

A Focus On Long-term Growth In Biotech – Dr. Jason Kantor – Rbc Capital Markets

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS